warfarin teva tafla 1 mg
teva b.v.* - warfarinum natríum - tafla - 1 mg
rimactan hart hylki 300 mg
sandoz gmbh* - rifampicinum inn - hart hylki - 300 mg
rimactan hart hylki 150 mg
sandoz gmbh* - rifampicinum inn - hart hylki - 150 mg
prograf hart hylki 0,5 mg
astellas pharma a/s* - tacrolimusum mónohýdrat - hart hylki - 0,5 mg
prograf hart hylki 1 mg
astellas pharma a/s* - tacrolimusum mónohýdrat - hart hylki - 1 mg
prograf hart hylki 5 mg
astellas pharma a/s* - tacrolimusum mónohýdrat - hart hylki - 5 mg
warfarin teva tafla 3 mg
teva b.v.* - warfarinum natríum - tafla - 3 mg
orserdu
stemline therapeutics b.v. - elacestrant - brjóstakrabbamein - innkirtla meðferð - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.
everolimus wh tafla 5 mg
williams & halls ehf. - everolimusum inn - tafla - 5 mg
dasatinib accord
accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - Æxlishemjandi lyf - dasatinib accord is indicated for the treatment of adult patients with:• ph+ acute lymphoblastic leukaemia (all) with resistance or intolerance to prior therapy. dasatinib accord is indicated for the treatment of paediatric patients with:• newly diagnosed ph+ all in combination with chemotherapy.